



**Jenifer Bouey, MD, PhD**  
**Tang Chair in China Policy Studies, RAND Corporation**

Jennifer Huang Bouey, M.D. Ph.D. is a Senior Policy Researcher and Tang Chair in China Policy Studies at the RAND Corporation. As an epidemiologist with training in clinical medicine and quantitative methods, Dr. Bouey's research centers on social determinants of health among marginalized populations.

Prior to joining RAND, she taught Epidemiology at Georgetown University for 14 years and led studies on the health risks and health care access barriers among immigrants, rural-to-urban migrants, sexual minorities, and people at high-risk for HIV in the U.S. and China. Between 2015-2018, she organized an international multi-disciplined research workgroup on issues that are critical to U.S. and China's health security interests, including pandemic preparedness, global health governance, and health risks among South-to-South migrants.

Dr. Bouey served on study sections at the NIDA, NIMH, and Fogarty Center of the National Institute of Health, and as an expert reviewer for the China Natural Science Foundation, Hong Kong AIDS Council, and Hong Kong Government Research Fund. Dr. Bouey also served as a consultant to the World Bank, Clinton HIV/AIDS Initiative, the Save the Children Federation, Inc., and China's National Centers for Disease Control.

Dr. Bouey received her Master of Public Health degree and Ph.D. degree in Epidemiology from the George Washington University and her Clinical Medicine (M.D.) Degree from the Peking University School of Medicine.

### **Questions for the Panelist**

- What role does your agency play overseeing Chinese activities in U.S. health, biotech, and dietary supplement industries?
- What authorities and regulations can your agency exercise to govern Chinese investments and business arrangements in U.S. health, biotech, and dietary supplement industries?
- What concerns exist regarding China's activities in the U.S. biotechnology industry? Are existing regulations sufficient for addressing these concerns?
- To what extent do U.S. pharmaceuticals and dietary products rely on supply chains involving manufacturing plants based in and/or active ingredients sourced from China?
- How do you expect the domestic U.S. pharmaceutical and dietary supplement industries to change in the next five years with regard to where active ingredients, labor, or other inputs are located and sourced from?
- What are the national security risks—including the ability to protect and address the health needs of our men and women in uniform, emergency responders, and the public—from current and potentially increasing levels of dependence on Chinese health products?
- What is China's record of compliance on agreements with the United States regarding pharmaceuticals, medical products, dietary supplements, and biotechnology (agreements should include formal agreements and any commitments made during JCCT, S&ED or other fora)?
- Are existing authorities and regulations sufficiently able to address the challenges presented by China's role in global medical and pharmaceutical supply chains?